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Abstract: Owing to the suppression of immune responses and associated side effects, steroid 
based treatments for inflammatory encephalitis disease can be detrimental. Here, we dem-
onstrate a novel carbon nanosphere (CNP) based treatment regime for encephalomyelitis in 
mice by exploiting the functional property of the nuclear matrix binding protein SMAR1. 
A truncated part of SMAR1 ie, the DNA binding domain was conjugated with hydrothermally 
synthesized CNPs. When administered intravenously, the conjugate suppressed experimental 
animal encephalomyelitis in T cell specific conditional SMAR1 knockout mice (SMAR-/-). 
Further, CNP-SMAR1 conjugate delayed the onset of the disease and reduced the demyelination 
significantly. There was a significant decrease in the production of IL-17 after re-stimulation 
with MOG. Altogether, our findings suggest a potential carbon nanomaterial based therapeutic 
intervention to combat Th17 mediated autoimmune diseases including experimental autoim-
mune encephalomyelitis.
Keywords: carbon nanospheres, EAE, IL-17, SMAR1, Th17
Introduction
Globally, more than 2.3 million people are affected by multiple sclerosis (MS), an 
autoimmune disorder.1 It is an inflammatory disease caused by the destruction of 
the myelin sheath of the central nervous system (CNS). The pathogenesis is due to 
the deregulated immune responses mediated by a subset of T cells known as Th17 
cells.2 MS causes physical and mental complications due to partial paralysis, lack of 
co-ordination, and aberrant neuronal communication from the brain and spinal cord.3 
There is no known cure for the disease though immunosuppressive and immunomodu-
latory therapy is currently employed to alleviate MS.4 Moreover, the immunomodula-
tory (steroids and interferon) or replenishing (glatiramer acetate) treatment for MS 
has adverse side effects.5,6 Experimental autoimmune encephalomyelitis (EAE) is an 
animal model of human CNS demyelinating diseases, including MS and acute dis-
seminated encephalomyelitis. It serves as a typical disease model of T cell mediated 
autoimmune disease. Purified myelin or myelin proteins such as MBP, PLP, MOG 
or its peptide are used to induce EAE in rodents.7 Recent interest in the field of T cell 
biology envisaged the molecular mechanism of EAE disease and elucidated that IL-17 
secreting Th17 subset of T cells was the causative mediator of the disease.8 EAE dis-
ease progression can be prevented by factors or signaling molecules that control Th17 
immune reaction, IL-17 secretion or its gene expression. Thus, EAE is considered to 
be a Th17 driven autoimmune inflammatory disease.9
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In the present study, we hypothesized that using 
nanoparticles to deliver an anti-inflammatory protein SMAR1 
could combat the EAE disease progression. SMAR1 was 
identified as a nuclear matrix binding protein attached to 
an AT-rich MARβ region of the TCRβ locus.10 Aberrant 
expression of SMAR1 had physiological consequences with 
modulation of T cell repertoire and perturbation of mounting 
effective immune responses.11 A recent report suggested a 
critical role of SMAR1 in the orchestration of T cell differ-
entiation programs and its implications in asthma disease 
progression. SMAR1 binds to AT-rich MAR regions present 
on the promoters of T-bet and IL-17 with its C-terminal DNA 
binding domain (DBD). It functions as a negative regulator 
of Th1 and Th17 cell differentiation.12 SMAR1 epigenetically 
modulates the target genes by the recruitment of chromatin 
modifying complexes and altering the gene transcription 
machinery.13,14 Since deficiency of SMAR1 leads to increased 
Th17 responses, we hypothesized that SMAR1 deficiency 
might aggravate Th17 driven EAE disease. We assumed that 
SMAR1 could function as a therapeutic protein for Th17 
mediated autoimmune diseases. The gated channels and 
membrane proteins in cells tightly regulate protein delivery, 
which is a challenge in an in vivo scenario. The development 
of protein transduction platforms would therefore signifi-
cantly increase the scope of potential applications for protein 
therapeutics. Nanoscale drug delivery systems are used for 
delivery of drugs/proteins due to their small size and a high 
surface to volume ratio. Recently, various nanoparticles were 
used for protein transport, including nanoparticle stabilized 
nano-capsules,15 hollow polymeric nanoparticles,16 and chi-
tosan nanoparticles.17,18 For delivery of SMAR1 to the site 
of inflammation, we employed carbon nanospheres (CNPs) 
as a carrier. CNPs have been explored as drug carriers and 
have been shown to penetrate the biological barriers with 
low cytotoxicity.19,20 Utilizing this property, we investigated 
the efficacy of carbaon nanoparticle based treatment in the 
EAE disease model.
Materials and methods
animal model
T cell specific (Lck [early]-Cre SMAR1f/f) conditional 
knockout mice (SMAR1-/-)10 and wild type (WT) C57BL/6J 
mice were inbred in the animal facility of the National Centre 
for Cell Science (Pune, India). Animal experiments were 
done with 6–8-week-old mice. All animal-handling proce-
dures were performed according to the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of 
Health and followed the guidelines of the Animal Welfare 
Act. All animal experiments were approved by the Animal 
Ethical Committee of National Center for Cell Science, 
Pune, India.
synthesis of nanoparticles
Dextrose (0.6 M; HiMedia, Mumbai, India) solution was 
transferred to a Teflon-lined stainless steel vessel. The sealed 
vessel was kept in a muffle furnace at 180°C for 2 hours. The 
vessel was immediately removed after the reaction time and 
allowed to cool. The brown color colloidal suspension formed 
during the reaction was collected, washed, and re-suspended 
in deionized water for further use.
size and zeta potential
The size and zeta potential of the CNPs was examined 
by dynamic light scattering using Delsa Nano Zeta sizer 
(Beckman Coulter Incorporation, Brea, CA, USA). For 
estimating size, 0.1 mg/mL CNP in de-ionized water was 
used. The same sample was used for zeta potential analysis 
to establish the charge on the CNPs.
Fourier transform infrared spectroscopy 
analysis
CNP powder mixed with potassium bromide (Sigma-Aldrich 
Co., St Louis, MO, USA) was pelleted and analyzed for 
functional groups present by fourier transform infrared 
spectroscopy (FTIR) (Model Spectrum One; PerkinElmer 
Inc., Waltham, MA, USA). Spectra were recorded in the 
4,000–500 cm-1 wave number range.
atomic force microscopy analysis
A diluted sample of CNPs in deionized water was air dried 
on a coverslip and imaged under non-contact mode using an 
atomic force microscopy (AFM) (Witech, Ulm, Germany) 
with budget sensor probes. The nanoparticle conjugated 
protein sample was prepared as above and imaged in contact 
mode. The measurements were performed under ambient 
conditions with a scan speed of the 1 µm/s.
MTT assay
Splenocytes were isolated from mice and CD4+ T cells were 
further enriched using negative magnetic separation and flow 
cytometry. CD4+ T cells were cultured with a density of 2×106 
cells/mL in Roswell Park Memorial Institute (RPMI) 1640 
complete medium with 10% fetal bovine serum (FBS) with 
plate bound CD3 and CD28 for 48 hours. Different concen-
trations of CNPs (0.1, 1, and 10 µg/mL) were added and the 
cells were incubated for 24 hours followed by addition of 
10 µL of 5 mg/mL MTT (Sigma-Aldrich Co.). After 4 hours 
the formazan crystals were dissolved in 100 µL of dimethyl 
sulfoxide and the plate was read at 570 nm.
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Internalization of cNPs by Facs using 
CD4 and fluorescein isothiocyanate
Splenocytes were isolated from C57BL/6J mice to analyze 
the internalization of CNPs inside the cells. Cells (1×106/mL) 
were cultured in RPMI 1640 complete medium supplemented 
with 10% FBS with antibiotics and kept at 37°C in a humidi-
fied atmosphere saturated with 5% CO
2
. CNP-fluorescein 
isothiocyanate (FITC) conjugate was prepared by over-
night incubation of CNPs and FITC. CNPs or CNP-FITC 
(25 µg/mL) were added to the cells for different time periods 
(2 hours and 24 hours). Cells were washed thoroughly 4–5 
times and stained with CD4-allophycocyanin (APC) (1:1,000) 
for 30 minutes at 4°C. Cells were then washed with excess 
fluorescence-activated cell sorting (FACS) buffer (phosphate 
buffered saline [PBS] +2% FBS) and resuspended in 300 µL 
of FACS buffer. The cells were analyzed for FITC internaliza-
tion and CD4 staining using FACS CANTO (BD Biosciences, 
San Jose, CA, USA). Data from the flow cytometer were then 
analyzed using FACS DIVA software (BD Biosciences).
Immune response of cNPs in sera 
of mice
To understand whether the CNP-conjugate elicits any 
antigen-specific immune responses in vivo, CNP-conjugate 
(50 µg/mice) was injected intravenously. The immuno-
globulin measurements were done after 7 days using a 
mouse immunoglobulin assay kit (BD Biosciences). All the 
immunoglobulins, including IgG1, IgG2a, IgG2b, IgG3, IgM, 
IgA, Igλ, and Igκ were measured and a graph was plotted 
with dilution versus optical density (OD).
Facs
Anti-CD4, anti-CD62L, anti-CD44, anti-CD25, and anti-IL-17 
were purchased from BD Biosciences. Naïve T cell isolation 
was done as previously described.10 CD4+ T cells were first 
enriched by magnetic-activated cell sorting beads (autoMACS; 
Miltenyi Biotec, San Jose, CA, USA), and then further purified 
using FACS ARIA (BD Biosciences) with .95% purity. 
In vitro Th17 polarization from naïve 
T cells
Sorted naïve CD4+ CD25- CD62LhiCD44lo T cells were 
activated with plate-bound anti-CD3e (1 µg/mL; 2C11) 
and anti-CD28 (2 µg/mL; 37.51) in the presence of IL-6 
(10 ng/mL), TGF-β (R&D Systems, Inc., Minneapolis, 
MN, USA) (5 ng/mL), anti-IFN-γ (10 µg/mL), and anti-
IL-4 (10 µg/mL). All the antibodies were obtained from 
BD Pharmingen (San Jose, CA, USA) unless mentioned 
otherwise. Cells were cultured in RPMI 1640 (Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA) supplemented with 
10% FBS with antibiotics and kept at 37°C in a humidified 
atmosphere saturated with 5% CO
2
. CD4+ T cells primed for 
4 days in wells were expanded on day 4 with/without (for 
Th17 culture) 50 U mL-1 IL-2 until day 7.
eae induction
Induction of EAE in mice was performed as described earlier.8 
Briefly, active EAE was induced by immunization with 300 
(for survival analysis) or 150 µg (for all other experimental 
analysis) MOG p35–55 emulsified in complete Freund’s 
adjuvant (CFA) (Sigma-Aldrich Co.), supplemented with 
400 µg/mL Mycobacterium tuberculosis. Flanks of each leg 
received emulsions as four subcutaneous injections (50 µL). 
Also, 200 ng pertussis toxin (Sigma-Aldrich Co.) dissolved 
in 200 µL PBS was injected intraperitoneally on days 0 and 
2 after immunization. Data of survival group of mice during 
experimentation was plotted using GraphPad Prism software. 
Clinical assessment of EAE was performed daily after disease 
induction according to the following criteria: 0, no disease; 1, 
decreased tail tone; 2, hind limb weakness or partial paralysis; 
3, complete hind limb paralysis; 4, forelimb and hind limb 
paralysis; 5, moribund state. Daily clinical scores were cal-
culated as the average of all individual disease scores of each 
group, including mice not developing clinical signs of EAE.
re-stimulation experiments with MOg 
This experiment was done to check the efficiency of the 
CD4+ T cells from control and CNP-conjugate treated mice 
to secrete pro-inflammatory cytokine IL-17. Briefly, spleno-
cytes were isolated from control and treated mice 20 days 
post-immunization for EAE disease. These cells were cul-
tured in the presence of increasing concentrations (10 and 
50 µg/mL) of MOG to re-stimulate the T cells. Supernatants 
were analyzed to quantify the secretion of IL-17 measured 
with DuoSet enzyme-linked immunosorbent assay (ELISA) 
kits (R&D Systems, Inc.). ELISA plates were developed 
with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (BD 
Pharmingen), and read with a microplate reader (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). 
Intracellular cytokine staining
For intracellular cytokine staining, in vitro cultured cells 
were re-stimulated with phorbol myristate acetate (Sigma-
Aldrich Co.; 50 ng/mL) and ionomycin (Sigma-Aldrich Co.; 
1 mM) for 4 hours. GolgiStop (BD Biosciences) was added 
during the last 3 hours of re-stimulation. After staining for 
extracellular markers, cells were fixed, permeabilized, and 
stained intracellularly for specific cytokines. IL-17-PE and 
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CD4-PerCP Cy5.5, (BD Biosciences) were used. Cells were 
analyzed on a FACS CANTO flow cytometer (BD Biosci-
ences), and data analyzed by FACS DIVA software.
Dot blot assay
In this assay, the promoter fragment of IL-17 was ampli-
fied by polymerase chain reaction (PCR) and spotted on 
the membrane and allowed to bind at 37°C. The membrane 
was blocked with BSA followed by addition of conjugate of 
gold nanoparticles and SMAR1 DBD. For the conjugation of 
gold nanoparticles and protein, the pH of synthesized gold 
nanoparticles was adjusted to 9 by using potassium carbonate, 
followed by protein addition and incubation for 10 minutes 
at room temperature. After centrifugation at 10,000 rpm 
for 10 minutes, 2 µL of the conjugated pellet was used for 
the assay. The membrane was washed several times with the 
buffer and checked for the red color formation indicating the 
binding of the protein to the promoter fragment.
chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were done 
as previously described.10 In brief, naïve CD4+ T cells 
polarized under various conditions were treated with 1% 
formaldehyde to crosslink protein to DNA. Cells were lysed, 
and chromatins were sheared to ~500 bp using a biorup-
tor (Diagenode, Rue Bois Saint-Jean, Seraing, Belgium). 
Cells were then subjected to immunoprecipitation with 
anti-pSTAT3 (Santa Cruz Biotechnology Inc., Dallas, TX, 
USA). Control isotype (purified rabbit IgG) was also used 
to normalize the non-specific binding. After de-crosslinking, 
the immunoprecipitated chromatin DNA was PCR amplified 
for STAT binding region of the SMAR1 promoter (SPr) for-
ward: 5′-GCCACTGAACGAGCCCGGAA-3′ and reverse: 
5′-AGTCTCTGCGGCCATGATTT-3. PCR conditions used 
were: 95°C for 5 minutes, 95°C for 30 seconds, 58°C for 
30 seconds, 72°C for 45 seconds (40 cycles), and 72°C for 
10 minutes. The resulting DNA was also analyzed by real-
time PCR to determine the relative enrichment (2^ (ΔCt of 
the control–ΔCt of the sample)).
Immunofluorescence staining
Purified naïve CD4+ T cells were cultured under unstimulated 
conditions (Th0). Cells were harvested and fixed in 4% para-
formaldehyde, permeabilized with 0.1% Triton X-100, and 
incubated with anti-SMAR1 (Bethyl Laboratories, Montgom-
ery, TX, USA) or anti-SMAD, (Santa Cruz Biotechnology Inc.) 
antibodies. They were counterstained using the anti-mouse or 
anti-rabbit fluorescently labeled secondary antibodies (EMD 
Millipore, Billerica, MA, USA). For nuclear staining, cells 
were treated with 4,6-diamidino-2-phenylindole dihydrochlo-
ride (Fluka, St Louis, MO, USA). Cytospinning was done to 
mount the cells onto the confocal slides. Coverslips were then 
mounted with fluorescent mounting media (Dako Denmark 
A/S, Glostrup, Denmark) and examined under a Zeiss LSM-
510 meta confocal laser scanning microscope (Carl Zeiss 
Meditec AG, Jena, Germany).
Quantitative real-time Pcr and Western 
blotting
Gene expression was examined using a thermocycler 
(Eppendorf, Hauppauge, New York, NY, USA) with an iQ 
SYBR Green Real-Time PCR kit (Bio-Rad Laboratories 
Inc.). Data were normalized to expression of GAPDH 
(reference gene). Transcripts of SMAR1 forward: 
5′-GCATTGAGGCCAAGCTGCAAGCTC-3′, reverse: 5′-CG
GAGTTCAGGGTGATGAGTGTGAC-3′, GAPDH forward: 
5′-AATTCAACGGCACAGTCAAAGCCGAGAATG-3′, 
reverse: 5′-GCGGCACGTCAGATCCACGCAGGAC-3′ were 
amplified by PCR. For immunoblot analysis, 50 µg of protein 
from whole T cell lysates was resolved by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis. After transferring 
the proteins to polyvinyl difluoride membrane it was probed 
using SMAD1/2/3, pSTAT3 (Santa Cruz Biotechnology 
Inc.), SMAR1 (Bethyl Laboratories), and β-actin (Santa Cruz 
Biotechnology Inc.) antibodies using a standard protocol.
Results
synthesis and characterization of 
nanospheres
The carbon nanoparticles were synthesized in a Teflon lined 
vessel containing 0.6 M dextrose solution at 180°C for 2 hours. 
After the reaction, the particles were washed and suspended in 
deionized water for further use. The synthesized nanoparticles 
were imaged by AFM in contact and non-contact mode with 
probes supplied by budget sensors. Measurements were per-
formed in ambient conditions. Image resolution was between 
256×256 pixels with a scan speed of 1 µm/s. Next, we 
sought to analyze the shape of the nanoparticles. For this, 
we utilized AFM. From the data we received from AFM, we 
confirmed that the particles had symmetrical spherical mor-
phology (Figure 1A). After conjugating the protein with nano-
particles, the particles have a tendency to aggregate into small 
clusters deviating from their natural colloidal nature which 
is clearly evident in the AFM images (Figure 1B). To avoid 
this clustering, the particles were sonicated for 15 seconds to 
bring them back to their colloidal nature, making them func-
tionally active. The functional groups on nanoparticles were 
measured using FTIR. By using this technique, we acquired 
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infrared spectrum of absorption of the nanoparticles. The 
surface functional groups on carbon nanospheres were mainly 
the -OH and the C=O groups confirmed by FTIR. The band 
observed at 1,725–1,700 cm-1 can be assigned to the carbonyl 
groups of aldehydes. The broad band at 2,900–3,200 cm-1 
can be allocated to -OH bonds (Figure 1C). The presence of 
hydroxyl and carbonyl groups made the CNPs hydrophilic, 
and the particles were readily dispersible in water. The con-
jugated nanoparticles showed an increased size (Figure 1D). 
The interaction of nanoparticles with the biological samples 
depends on the charge of the nanoparticles. The zeta poten-
tial of the carbon nanospheres dispersed in deionized water 
was found to be -22 mV. When the carbon nanospheres 
were conjugated with DBD of SMAR1, coated with PEG 
(~8,000 MW), the zeta potential shifted to positive, confirm-
ing conjugation (Figure 1E). The schematic representation 
of nanoparticles conjugated with the SMAR1 protein is 
represented in Figure 1F.
Toxicity and internalization of carbon 
nanospheres
After synthesizing the carbon nanospheres, they were further 
evaluated for toxicity in T cells using MTT assay. As shown 
in Figure 2A, increasing the concentration of CNPs did not 
Figure 1 synthesis and characterization of carbon nanoparticles and the cNP sMar1 conjugate.
Notes: (A) aFM image of the spherical carbon nanoparticles, (B) aFM image of carbon nanoparticles conjugated with DNa binding domain of sMar1, (C) FTIr analysis 
of synthesized carbon nanospheres showing the presence of surface hydroxyl and carbonyl groups, (D, E) zeta size and zeta potential of the bare carbon nanoparticles and 
carbon nanoparticles sMar1 conjugate respectively, showing shift in size and potential when conjugated with sMar1. (D) cNPs (black) and cNP sMar1 conjugate (blue); 
(E) cNPs (blue) and cNP sMar1 conjugate (black). (F) covalent conjugation scheme of cNPs with sMar1 DBD protein.
Abbreviations: aFM, atomic force microscopy; FTIr, Fourier transform infrared spectroscopy; cNPs, carbon nanospheres; DBD, DNa binding domain; eDc, 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide.
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have any toxic effect on the cells. No toxicity was shown 
in 100 ng and 1 µg of nanoparticles. While the increasing 
concentration of nanoparticles (10 µg/mL) hindered the 
absorbance, no toxicity was shown in 100 ng and 1 μg of 
nanoparticles. These data conclude that CNPs were non-toxic 
to the survival of T cells.
Since we noticed that CNPs were non-toxic to T cells, 
their uptake by the T cells was analyzed using FACS. 
As shown in Figure 2B, uptake of nanoparticles was observed 
in T cells within 2 hours of treatment. This result shows that 
CNPs can efficiently pass through the cell membrane of 
T cells, which might be through non-specific pinocytosis.
Immune response of carbon nanospheres
Since we knew that the CNPs were non-toxic to the T cells, 
it intrigued us to investigate the effect of these nanoparticles 
Figure 2 cNPs are internalized into the T cells. 
Notes: (A) cell viability of T cells when exposed to different concentrations of cNPs for 24 hours. (B) Uptake of FITc labeled cNPs in T cells isolated from splenocytes 
of mice after 2 and 24 hours at 37°c, 5% cO2 in complete rPMI 1640 with antibiotics. Data represent two independent experiments.
Abbreviations: CNPs, carbon nanospheres; RPMI, Roswell Park Memorial Institute medium; FITC, fluorescein isothiocyanate.
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in vivo. One of the major hurdles of nanoparticle research is 
to avoid the unwanted and non-specific physiological effects 
or side effects of the nanoparticles. To verify whether the 
CNP-SMAR1 conjugate induces any unwanted immune 
responses in mice, 50 µg of the CNP-protein conjugate 
was injected intravenously. A complete immunoglobulin 
profiling was done in the sera of these mice 7 days after 
injection. Sera were diluted 1,000 times, and serial dilutions 
were made to analyze significant changes in the antibody 
titration by measuring the OD at 600 nm. As shown in 
Figure 3, no specific immune response was elicited against 
the CNPs evidenced by the similar levels of IgGs. IgM 
showed marginal induction that may be due to negligible 
non-specific immune response. The results suggested that 
CNPs did not induce endogenous immune response even 
after intravenous administration.
regulation of sMar1 during Th17 
differentiation
Recent research interest in T cell biology focused more on 
the regulation of Th17 cells as they are crucial for elicitation 
of inflammatory and autoimmune responses.2 Our previous 
report suggested that SMAR1 is downregulated in both pro-
inflammatory Th1 and Th17 cells.10 A series of experiments 
were performed to check the role of SMAR1 in Th17 dif-
ferentiation. Western blot analysis showed reduced SMAR1 
expression at different time points of Th17 differentiation that 
is inversely correlated with increased pSTAT3 and SMAD 
activation (Figure 4A). We have described a crucial MAR 
binding site on the IL-17A promoter where SMAR1 binds 
through direct interaction.12 To validate the binding ability 
of SMAR 1 proteins’ DBD (SMAR1 DBD) with the IL-17 
promoter, it was evaluated by dot blot assay. In this test 
Figure 3 Immune response of carbon nanoparticles. 
Notes: serum levels of different Iggs from the mice after 7 days of intravenous administration of cNPs (50 µg) as compared to placebo (PBs) injected mice. The best of 
two independent experiments is represented.
Abbreviations: cNPs, carbon nanospheres; PBs, phosphate buffered saline; OD, optical density.
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Figure 4 regulation of sMar1 during Th17 differentiation is mediated by Il-6 and sTaT3.
Notes: (A) Western blotting analysis of sMar1 during the different time points of Th17 differentiation with TgF-β and Il-6. psTaT3 and sMaD1/2/3 complexes were also 
counter-stained along with actin as loading control. (B) Specificity of the SMAR1 conjugated carbon nanospheres to bind to the IL-17 promoter. Dot blot cassettes showing 
the binding of gold nanoparticle/sMar1 DBD conjugate with the Il-17 promoter DNa spotted on the membrane. The control had only nanoparticles spotted on it. The 
second cassette was spotted with gold nanoparticles/sMar1 DBD conjugate and in the third cassette conjugate of gold nanoparticle sMar1 protein interacting domain was 
spotted as a control. color development was seen where the cNP/sMar1 DBD conjugate was spotted, indicating a binding of this protein with the DNa, whereas the 
sMar1 protein interacting domain did not show color formation. (C) confocal analysis of single cells after the treatments of TgF-β and/or Il-6 were performed to check 
the differential expression of sMar1 (red) together with sMaD1/2/3 (green). (D) Naïve T cells were cultured under Th17 differentiating condition for 7 days and sMar1 
expression was analyzed by immunoblotting along with psTaT3 and sMaD1/2/3. (E) Quantification of SMAR1 mRNA after differential treatment of TGF-β/Il-6 or together 
using real-time Pcr. hPrT was used as an internal control. (F) luciferase assay was done on sPr luc (sMar1 promoter) region after transient transfection into 293T cells 
and exogenous TgF-β or Il-6 was added. For all treatments 5 ng/ml of TgF-β or 10 ng of Il-6 were used. (G) relative enrichment of phosphor sTaT3 was analyzed on the 
sMar1 promoter. *P#0.05; **P#0.01; one-way analysis of variance with Tukey’s post hoc test relative to the untreated T cells. Data shown are mean ± standard error and 
representative of two to three independent experiments (n=3–4 mice). 
Abbreviations: DBD, DNa binding domain; Pcr, polymerase chain reaction; hPrT, hypoxanthine-guanine phosphoribosyltransferase; cNP, carbon nanosphere.
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the promoter fragment amplified by PCR was spotted and 
allowed to bind to the membrane at 37°C. Subsequently, the 
membrane was blocked with BSA and then the conjugate 
of gold nanoparticles and SMAR1 DBD was added. The 
membrane was washed several times with the buffer and 
checked for a red color formation that indicated the binding 
of protein to the IL-17 promoter (Figure 4B). This experiment 
showed the direct binding interaction of SMAR1 DBD to the 
IL-17 promoter in the absence of full-length protein. SMAR1 
down-regulation during Th17 differentiation was further 
verified by confocal analysis with TGF-β or IL-6 alone or 
combined. The result revealed a drastic down-regulation of 
SMAR1 (red) under TGF-β and IL-6 combined signaling. 
SMAD1/2/3 proteins (green) were used as positive controls 
(Figure 4C). 
To understand the signaling factors inhibiting SMAR1 
under Th17 condition, TGF-β and IL-6 were administered 
separately or together in the cultures. SMAR1 expression 
was observed to be inversely correlated with IL-6 medi-
ated pSTAT3, and not with SMAD signaling, at the protein 
(Figure 4D) as well as at the transcription levels (Figure 4E). 
Results from the real-time experiment showed us the quanti-
fication of SMAR1 gene expression, which is regulated at the 
transcription level. To further understand the IL-6 mediated 
down-regulation of SMAR1 gene expression, we performed 
luciferase assay using SMAR1 promoter luciferase construct 
and supplementation of TGF-β or IL-6 separately. We 
observed an IL-6 dependent down-regulation of SMAR1 
promoter activity (Figure 4F) but not with TGF-β treatment. 
Since SMAR1 was downregulated after IL-6 treatment and 
activation of STAT3, we assumed SMAR1 gene would be 
negatively regulated by pSTAT3. ChIP assays were carried 
out for the relative enrichment of pSTAT3 on the SMAR1 
promoter, during Th17 differentiation programs. As shown 
in Figure 4G, we noticed specific enrichment of pSTAT3 
on SMAR1 promoter during the later time points in Th17 
differentiated cells. These results confirm that regulation of 
SMAR1 is a distinctly controlled mechanism specific to Th17 
differentiation pathway. 
sMar1 knockout mice susceptible 
to eae
To confirm the effect of SMAR1 on Th17 differentiation 
and associated inflammation, we employed a classic Th17 
mediated EAE model in mice. For this WT and SMAR1-/- 
mice were immunized with MOG in CFA subcutaneously 
along with Bordetella pertussis vaccine. After inducing 
the disease with normal 300 µg of MOG, a severe disease 
progression and death of SMAR-/- mice was observed com-
pared to the WT mice (six out of eight mice) (Figure 5A). 
A low level of MOG (150 µg/mice) induced severe neuronal 
impairment in SMAR1-/- mice with a lack of coordina-
tion, severe difficulty in walking, and associated paralysis 
of limbs (no death was observed during this treatment). 
We noticed early and enhanced disease progression in 
SMAR1-/- mice compared to the WT mice (Figure 5B). 
Histology sections revealed progressive cell infiltrations 
in the spinal cord of SMAR1-/- mice (Figure 5C). Next, 
to understand the efficiency of IL-17 secretion of T cells 
from WT and SMAR1-/- mice, splenocytes from MOG 
stimulated mice 40 days post-immunization were isolated 
and re-stimulated with MOG. The secretion of IL-17 by 
the splenic T cells after re-stimulation of MOG was also 
high (double) in the SMAR1-/- mice compared to the WT 
mice (Figure 5D). The pro-inflammatory cytokine IL-17 
plays a pathogenic role in EAE progression.17 To this end, 
we checked the IL-17 level from WT and SMAR1-/- mice. 
Flow cytometric data showed the expression of IL-17 was 
significantly high in SMAR1-/- mice compared to WT 
mice (Figure 5E). Thus, SMAR1 deficiency in T cells 
caused aberrant immune responses with physiological 
consequences in vivo. 
effect of cNP/sMar1 DBD conjugate 
on eae mice
EAE is a well-established model for Th17 mediated CNS 
autoimmune inflammation against myelin protein.8 T cells 
activated against MOG cross the blood–brain barrier, dis-
rupted due to pertussis toxin. The MOG reacts against the 
myelin protein causing the formation of white plaque in the 
brain and spinal cord. Further, in this disease, more immune 
cell infiltration into the CNS and symptomatic paralysis of 
the peripheral organs in mice is seen. Initial subcutaneous 
administration of MOG in CFA activates the T cells against 
the antigen in the mice. These activated T cells react with 
the similar myelin protein in the CNS and induce IL-17 
mediated inflammation and demyelination.9 Previous results 
suggest that SMAR1 acts as a negative inhibitor of Th17 
mediated inflammation. Our data showed that T cell specific 
SMAR1-/- knockout mice have been proven to have enhanced 
Th17 driven experimental animal encephalomyelitis. Thus, 
we assumed exogenous nanoparticle mediated delivery of 
SMAR1 into null T cells might reverse the disease pro-
gression in these susceptible mice, and this strategy can 
be utilized for replenishment therapy. For this, we induced 
EAE in SMAR1-/- mice with MOG and followed the disease 
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progression. An amount of 150 µg of MOG p35–55 peptide 
emulsified in CFA and containing 4 mg/mL of heat-killed 
Mycobacterium tuberculosis H37Ra was administered sub-
cutaneously in mice. Pertussis toxin (100 ng) was injected 
intraperitoneally on day 0 and 2. The mice were then 
randomly segregated into three groups. Two groups of mice 
were administered carbon nanospheres (25 µg/mice) and 
SMAR1 conjugated carbon nanospheres (25 µg/mice and 
SMAR1 50 µg/mice) respectively from day 7 onwards for a 
week (Figure 6A). PBS was administered as placebo in a third 
group of control mice. As shown in the clinical score plotted 
against the days post-immunization (Figure 6B), symptoms of 
the disease started appearing from the 10th day onwards with 
partial tail drooping. Control mice exhibited severe disease 
with complete tail and hind limb paralysis. We observed 
similar symptoms in the CNPs group. Interestingly, when 
we analyzed the CNP-protein conjugate group, the disease 
progression was significantly low. Moreover, the disease pro-
gression was halted at partial tail drooping with no paralysis 
of the limbs. Each group had five mice, and the results were 
statistically verified using two-way multiple-range analysis 
of variance (ANOVA) for multiple comparisons with P,0.01 
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Figure 5 Mice with SMAR1 deficient T cells are susceptible to EAE. 
Notes: (A) Survival graph of WT C57BL/6J and T cell specific conditional SMAR1 knockout mice with 300 µg MOg driven eae. *P#0.05; **P#0.01 according to the 
Kaplan–Meier survival statistical analysis. Data shown are mean ± standard error of the mean and representative of two to three independent experiments (n=3–4 
mice). (B) clinical scores of eae induced sMar1-/- and WT mice (with 150 µg of MOg) were plotted during the days post-administration. The P-values of clinical scores 
were determined by two-way multiple-range analysis of variance for multiple comparisons. *P#0.05 was considered significant and data shown are representative of two 
independent experiments with 5–7 animals. **P,0.01. (C) histology of the spinal cord showing the hematoxylin and eosin staining for cellularity. (D) splenocytes of the 
MOg treated WT and knockout (KO) mice (after 40 days) were re-stimulated with 50 µg/mL of MOG. IL-17 secretion of the T cells was measured using IL-17 specific ELISA. 
Data represent three independent experiments with P-values less than 0.05 considered significant by unpaired Student’s t-test compared to the WT MOg treated samples. 
*P#0.01. (E) Intracellular cytokine staining of WT and SMAR1 deficient T cells, stained with anti-IL-17; numbers in plot show percentage IL-17+ cells gated on cD4. Data 
represent two independent experiments with 3–4 mice.
Abbreviations: eae, experimental autoimmune encephalomyelitis; elIsa, enzyme-linked immunosorbent assay; WT, wild type.
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and P,0.005 considered significant. This result shows that 
conjugation of a nanoparticle with SMAR1 protein as low as 
50 µg/mice had a significant biological effect in combating 
the Th17 mediated EAE disease progression. 
To check whether the aberrant disease progression in 
CNP-SMAR1 treated mice is due to decreased ability of 
T cells to secrete IL-17, we analyzed the ability of T cells to 
react against re-stimulation of MOG peptide. T cells in our 
bodies respond vigorously when an exposed antigen is re-
administered to mount a secondary immune response. Thus, 
if the T cells are reacting against the antigen, it will secrete 
the cytokine specific to EAE disease, which is IL-17. For this, 
splenocytes from control, CNPs, and CNPs-SMAR1 treated 
mice were isolated and cultured at a density of 2×106 cells/mL 
in complete RPMI. MOG peptide was added at 10 µg and 
50 µg/mL concentration, and the splenocytes were cultured 
for 48 hours. Supernatants were harvested and analyzed for 
IL-17 cytokine secretion (Figure 6C) which clearly dem-
onstrated that the secretion of IL-17 in the CNPs SMAR1 
conjugate treated mice were three-fold lower compared to 
control or CNPs alone treated mice. These results verify 
that the CNP-SMAR1 conjugate renders resistance to EAE 
disease progression by blocking the secretion of IL-17 from 
T cells.
Discussion
The study shows that CNPs can be used as an efficient car-
rier system to deliver the proteins inside the cells. These 
CNPs can be utilized further in the most demanding field 
of protein-based therapeutics. Proteins like insulin, anti-
bodies, interleukins, etc are used in protein therapeutics. 
Recent research interest focuses more on direct delivery 
of proteins into mammalian cells and giving their func-
tional attributes by carbon nanotubes.15 Moreover, carbon 
Figure 6 effect of cNP/sMar1 DBD conjugate on eae mice. 
Notes: (A) schematic representation of the experimental timeline for administering the conjugate to eae mice and the criteria for clinical scores. (B) clinical scores of 
sMar-/- c57Bl/6J mice immunized with MOg p35–55 and cFa, and then administered phosphate buffer, cNPs, and conjugate for 19 days. The P-values of clinical scores 
were determined by two-way multiple-range analysis of variance for multiple comparisons. *P,0.01, **P,0.005 were considered significant. (C) splenocytes were isolated 
from control, NPs and conjugate treated mice and re-stimulated with different concentrations of MOg. supernatants were analyzed for the production of Il-17 through 
elIsa. Data represent two independent experiments with P-values less than 0.05 considered significant by unpaired Student’s t-test compared to the WT MOg treated 
samples. ***P#0.001.
Abbreviations: eae, experimental autoimmune encephalomyelitis; elIsa, enzyme-linked immunosorbent assay; cNP, carbon nanosphere; DBD, DNa binding domain; 
cFa, complete Freund’s adjuvant; sc, subcutaneously; ip, intraperitoneally; iv, intravenously; NPs, nanoparticles; WT, wild type.
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nanospheres have also been reported to cross the blood–
brain barrier and regulate gene expression. Here, the CNPs 
were synthesized through a green chemistry method that 
did not require any hazardous chemicals. The CNPs were 
spherical and had -COOH and -OH functionalities on their 
surface, making it easy for conjugation with proteins. The 
CNPs formed were ready to use without involving further 
treatments to make them favorable for conjugation. Toxicity 
of the carbon nanospheres was checked, and they were non-
toxic. As they were to be used as a carrier, internalization 
studies were carried out. FACS results suggested that CNPs 
entered the cells. Thus, these carbon nanospheres can be used 
as a carrier to deliver a protein. The nanospheres were also 
checked for their immunogenic property and were found 
to be non-immunogenic. They did not elicit any specific 
immune response, which is the primary concern when using 
nanoparticles for therapy. 
Reports from our group suggest that SMAR1 is down-
regulated under Th1 and Th17 differentiation conditions.12 
Delineating the path and signaling factors, we observed that 
IL-6 downregulated SMAR1 gene expression and not the 
TGF-β signaling alone. We had previously reported that 
SMAR1 can regulate IL-17 gene expression by directly 
binding to the promoter and epigenetically modifying the 
chromatin.12 In line with this, we show that deficiency of 
SMAR1 in T cells renders the mice susceptible to MOG 
driven EAE disease with higher IL-17 producing T cells. 
Thus, our conditional knockout mice model serves as an ideal 
scenario to investigate the reversal of the disease progression 
using exogenously supplemented SMAR1 protein associ-
ated with the nanoparticle-based delivery system. The non-
conditional SMAR-/- or complete knockout of SMAR1 is 
embryonically lethal.12 We employed CNPs to deliver the 
SMAR1 protein inside the T cells and modulate the immune 
response. SMAR1 is a 60 kda protein (548 amino acid). 
The region of 160–350 amino acids of SMAR1 contains 
arginine serine rich motifs and serves as a protein interac-
tion domain and C-terminal region whereas 350–548 amino 
acids region is characterized as DBD.21 Our results show 
that the C-terminal domain, ie, the DBD alone can serve 
an anti-inflammatory function. When the conjugate was 
administered to EAE induced conditional SMAR1-/- mice, 
the progression of the disease was slow as compared to the 
untreated SMAR1-/- EAE mice. The result was significant 
from the 14th–19th day of the disease. In the experiments 
conducted, mice injected only with CNPs were used as 
control. As can be noticed in Figure 6B, nanoparticle alone 
treated mice behaved similarly to the control untreated mice. 
We also analyzed the immune response when CNP-SMAR1 
was injected into mice (Figure 3) which showed minimal 
change in the IgGs compared to non-injected mice. From 
these results, we can conclude that nanoparticles were not 
inherently toxic to mice, which was a major concern as the 
conjugate might be delivered to other sites than T cells. CNP 
mediated delivery of SMAR1 DBD could efficiently repress 
the physiological disease condition of EAE in mice as the 
levels of IL-17 correspond to the pathogenesis of EAE. The 
distribution of CNP-SMAR1 was not checked in mice, as 
previous reports suggested permeability of CNPs to different 
organs like the liver and spleen. The CNPs do not remain 
in the organs and only a trace amount was seen 9 days after 
injection.19 In this report, we show that intravenous delivery 
of SMAR1 conjugated CNPs has an anti-inflammatory effect. 
In our study, we assessed the C-terminal domain of SMAR1 
(for the first time) to modulate EAE disease. This result is 
crucial when we consider using this protein in therapeutics, 
as a higher number of protein molecules can be loaded on a 
nanoparticle compared to the whole protein. By doing so, it 
can help us to reduce the therapeutic amount of protein used 
for controlling EAE. We propose that carbon nanoparticles 
can be used as an efficient protein carrier and that its pos-
sible applications in therapeutics should be investigated. 
A recent study has shown that nanoparticle mediated peptide 
delivery can be used to suppress autoimmune disease,22 and 
another report showed that an increase in the differentiation 
of T
regs
 suppressed the development of EAE.23 The use of 
CNP-SMAR1 DBD can be a good alternative for regulating 
unwanted autoimmune disease. 
Conclusion
The study demonstrated the excellent therapeutic efficacy 
of CNP/SMAR1 protein conjugate in controlling the EAE 
disease in SMAR1-/- mice. Here, we have shown for the first 
time that a domain of the protein, (DBD of SMAR1) can 
be used for controlling inflammation in EAE using CNPs. 
These data, along with the previously published research 
work highlight the potential of using carbon nanospheres 
and SMAR DBD conjugate for the treatment of EAE and 
controlling inflammation.
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